Megoxi (Megestrol Acetate)

Megestrol acetate binds to intracellular progesterone receptors, altering gene transcription and producing anti‑estrogenic effects in hormone‑sensitive tissues. It also stimulates hypothalamic pathways that increase appetite and promote anabolic metabolism, helping patients gain weight while inhibiting estrogen‑driven tumor growth.

The appropriate dose of Megoxi is determined by the prescribing clinician based on the individual’s medical condition, severity of weight loss, and response to therapy. Dosage adjustments are made according to clinical monitoring and therapeutic goals.

Safety of megesterol acetate in pregnancy and lactation has not been established. It is generally contraindicated unless the potential benefit justifies the potential risk to the fetus or infant, and it should be used only under close medical supervision in such situations.

To order Megoxi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Megoxi (megestrol acetate) is a progestin‑based appetite stimulant, offering both weight‑gain and anti‑estrogenic benefits, which distinguishes it from agents such as dronabinol or mirtazapine that act primarily on central nervous system pathways. Its dual action makes it useful in cancer‑related cachexia and hormone‑responsive tumors, though it carries a higher risk of metabolic and thrombotic side effects.

Megoxi tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Megoxi is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal discomfort. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risks associated with Megoxi include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, adrenal suppression leading to cortisol deficiency, severe hyperglycemia, and rare hypersensitivity reactions. Patients should be monitored regularly for signs of clotting, abnormal blood glucose, and any allergic symptoms.

Megoxi should be avoided in individuals with known hypersensitivity to megestrol acetate, active thromboembolic disease, uncontrolled diabetes, severe liver impairment, or in pregnant and breastfeeding women unless the benefits clearly outweigh the risks. It is also contraindicated in patients receiving concurrent high‑dose hormonal therapies without medical supervision.